121 related articles for article (PubMed ID: 8774418)
1. Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease.
Rösler N; Wichart I; Jellinger KA
J Neurol Neurosurg Psychiatry; 1996 Apr; 60(4):452-4. PubMed ID: 8774418
[TBL] [Abstract][Full Text] [Related]
2. Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia?
Rösler N; Wichart I; Bancher C; Jellinger KA
J Neural Transm Suppl; 1996; 47():259-66. PubMed ID: 8841971
[TBL] [Abstract][Full Text] [Related]
3. Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease.
Zimetti F; Caffarra P; Ronda N; Favari E; Adorni MP; Zanotti I; Bernini F; Barocco F; Spallazzi M; Galimberti D; Ricci C; Ruscica M; Corsini A; Ferri N
J Alzheimers Dis; 2017; 55(1):315-320. PubMed ID: 27662294
[TBL] [Abstract][Full Text] [Related]
4. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
5. Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients.
Rösler N; Wichart I; Jellinger KA
Acta Neurol Scand; 2001 Feb; 103(2):126-30. PubMed ID: 11227132
[TBL] [Abstract][Full Text] [Related]
6. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease.
Fukuyama R; Mizuno T; Mori S; Yanagisawa K; Nakajima K; Fushiki S
Eur Neurol; 2000; 43(3):161-9. PubMed ID: 10765057
[TBL] [Abstract][Full Text] [Related]
7. Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer's Disease.
Schmidt C; Gerlach N; Schmitz M; Thom T; Kramer K; Friede T; Zerr I
J Alzheimers Dis; 2015; 48(1):189-96. PubMed ID: 26401939
[TBL] [Abstract][Full Text] [Related]
8. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid.
Hesse C; Larsson H; Fredman P; Minthon L; Andreasen N; Davidsson P; Blennow K
Neurochem Res; 2000 Apr; 25(4):511-7. PubMed ID: 10823584
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.
Andreasen N; Vanmechelen E; Van de Voorde A; Davidsson P; Hesse C; Tarvonen S; Räihä I; Sourander L; Winblad B; Blennow K
J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):298-305. PubMed ID: 9527138
[TBL] [Abstract][Full Text] [Related]
10. Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.
Johansson P; Almqvist EG; Bjerke M; Wallin A; Johansson JO; Andreasson U; Blennow K; Zetterberg H; Svensson J
J Alzheimers Dis; 2017; 59(3):1017-1026. PubMed ID: 28697566
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease.
Pirttilä T; Koivisto K; Mehta PD; Reinikainen K; Kim KS; Kilkku O; Heinonen E; Soininen H; Riekkinen P; Wisniewski HM
Neurosci Lett; 1998 Jun; 249(1):21-4. PubMed ID: 9672379
[TBL] [Abstract][Full Text] [Related]
13. Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls.
Hahne S; Nordstedt C; Ahlin A; Nybäck H
Neurosci Lett; 1997 Mar; 224(2):99-102. PubMed ID: 9086466
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer's disease.
Arai H; Higuchi S; Sasaki H
Gerontology; 1997; 43 Suppl 1():2-10. PubMed ID: 9187933
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.
Blennow K; Hesse C; Fredman P
Neuroreport; 1994 Dec; 5(18):2534-6. PubMed ID: 7696597
[TBL] [Abstract][Full Text] [Related]
17. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype.
Fagan AM; Younkin LH; Morris JC; Fryer JD; Cole TG; Younkin SG; Holtzman DM
Ann Neurol; 2000 Aug; 48(2):201-10. PubMed ID: 10939571
[TBL] [Abstract][Full Text] [Related]
18. Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients.
Terrisse L; Poirier J; Bertrand P; Merched A; Visvikis S; Siest G; Milne R; Rassart E
J Neurochem; 1998 Oct; 71(4):1643-50. PubMed ID: 9751198
[TBL] [Abstract][Full Text] [Related]
19. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations.
Yamauchi K; Tozuka M; Nakabayashi T; Sugano M; Hidaka H; Kondo Y; Katsuyama T
Clin Chem; 1999 Apr; 45(4):497-504. PubMed ID: 10102909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
